Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Diabetes Obes Metab ; 25(6): 1698-1703, 2023 06.
Article in English | MEDLINE | ID: covidwho-2260455

ABSTRACT

AIM: There is conflicting evidence about the impact of the COVID-19 pandemic on the incidence of type 1 diabetes. Here, we analysed long-term trends in the incidence of type 1 diabetes in Italian children and adolescents from 1989 to 2019 and compared the incidence observed during the COVID-19 pandemic with that estimated from long-term data. MATERIALS AND METHODS: This was a population-based incidence study using longitudinal data from two diabetes registries in mainland Italy. Trends in the incidence of type 1 diabetes from 1 January 1989 to 31 December 2019 were estimated using Poisson and segmented regression models. RESULTS: There was a significant increasing trend in the incidence of type 1 diabetes of 3.6% per year [95% confidence interval (CI): 2.4-4.8] between 1989 and 2003, a breakpoint in 2003, and then a constant incidence until 2019 (0.5%, 95% CI: -1.3 to 2.4). There was a significant 4-year cycle in incidence over the entire study period. The rate observed in 2021 (26.7, 95% CI: 23.0-30.9) was significantly higher than expected (19.5, 95% CI: 17.6-21.4; p = .010). CONCLUSION: Long-term incidence analysis showed an unexpected increase in new cases of type 1 diabetes in 2021. The incidence of type 1 diabetes now needs continuous monitoring using population registries to understand better the impact of COVID-19 on new-onset type 1 diabetes in children.


Subject(s)
COVID-19 , Diabetes Mellitus, Type 1 , Child , Adolescent , Humans , Incidence , Diabetes Mellitus, Type 1/epidemiology , Pandemics , COVID-19/epidemiology , Italy/epidemiology , Registries
2.
J Clin Med ; 11(19)2022 Oct 10.
Article in English | MEDLINE | ID: covidwho-2240125

ABSTRACT

Primary bone marrow edema (BME) of the knee is still an elusive condition. This retrospective study was undertaken to gain insight into its characteristic features. The records of 48 patients with primary BME of the knee diagnosed by magnetic resonance imaging were reviewed. Demographic data, medical history, current medications, pain type, smoking and drinking habits, allergies, occupation, sports practiced, environmental factors, and life events predating symptom onset were examined. Data analysis demonstrated that 56.3% of patients had experienced a stressful event before BME pain onset and that 50% suffered from thyroid disorders. Standard conservative treatment resulted in pain resolution irrespective of the use of anti-inflammatories. However, most patients reported new persistent symptoms: dysesthesia/hypoesthesia on palpation in the skin area overlying the previous edema and a reduced ipsilateral patellar reflex. To our knowledge, this is the first study characterizing a substantial cohort of patients with BME. We found that middle-aged, sedentary, and slightly overweight women smokers are the typical patients with primary BME of the knee. The appearance and persistence of cutaneous dysesthesia/hypoesthesia at the site of the earlier lesion and ipsilateral patellar hyporeflexia implicate an autonomous nervous system dysfunction in BME pathogenesis and warrant further investigation.

3.
Lancet Diabetes Endocrinol ; 10(11): 786-794, 2022 11.
Article in English | MEDLINE | ID: covidwho-2106221

ABSTRACT

BACKGROUND: An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic. METHODS: For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006-19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker. FINDINGS: 87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality. INTERPRETATION: During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents. FUNDING: German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.


Subject(s)
COVID-19 , Diabetes Mellitus, Type 1 , Diabetic Ketoacidosis , Adolescent , Child , Humans , Diabetic Ketoacidosis/diagnosis , Diabetic Ketoacidosis/epidemiology , Diabetic Ketoacidosis/complications , Diabetes Mellitus, Type 1/diagnosis , Diabetes Mellitus, Type 1/epidemiology , Diabetes Mellitus, Type 1/complications , COVID-19/diagnosis , COVID-19/epidemiology , Pandemics , Prevalence , Registries
4.
Cherubini, Valentino, Marino, Monica, Scaramuzza, Andrea E.; Tiberi, Valentina, Bobbio, Adriana, Delvecchio, Maurizio, Piccinno, Elvira, Ortolani, Federica, Innaurato, Stefania, Felappi, Barbara, Gallo, Francesco, Ripoli, Carlo, Ricciardi, Maria Rossella, Pascarella, Filomena, Stamati, Filomena A.; Citriniti, Felice, Arnaldi, Claudia, Monti, Sara, Graziani, Vanna, De Berardinis, Fiorella, Giannini, Cosimo, Chiarelli, Francesco, Zampolli, Maria, De Marco, Rosaria, Bracciolini, Giulia Patrizia, Grosso, Caterina, De Donno, Valeria, Piccini, Barbara, Toni, Sonia, Coccioli, Susanna, Cardinale, Giuliana, Bassi, Marta, Minuto, Nicola, D’Annunzio, Giuseppe, Maffeis, Claudio, Marigliano, Marco, Zanfardino, Angela, Iafusco, Dario, Rollato, Assunta S.; Piscopo, Alessia, Curto, Stefano, Lombardo, Fortunato, Bombaci, Bruno, Sordelli, Silvia, Mameli, Chiara, Macedoni, Maddalena, Rigamonti, Andrea, Bonfanti, Riccardo, Frontino, Giulio, Predieri, Barbara, Bruzzi, Patrizia, Mozzillo, Enza, Rosanio, Francesco, Franzese, Adriana, Piredda, Gavina, Cardella, Francesca, Iovane, Brunella, Calcaterra, Valeria, Berioli, Maria Giulia, Lasagni, Anna, Pampanini, Valentina, Patera, Patrizia Ippolita, Schiaffini, Riccardo, Rutigliano, Irene, Meloni, Gianfranco, De Sanctis, Luisa, Tinti, Davide, Trada, Michela, Guerraggio, Lucia Paola, Franceschi, Roberto, Cauvin, Vittoria, Tornese, Gianluca, Franco, Francesca, Musolino, Gianluca, Maltoni, Giulio, Talarico, Valentina, Iannilli, Antonio, Lenzi, Lorenzo, Matteoli, Maria Cristina, Pozzi, Erica, Moretti, Carlo, Zucchini, Stefano, Rabbone, Ivana, Gesuita, Rosaria.
Frontiers in endocrinology ; 13, 2022.
Article in English | EuropePMC | ID: covidwho-1998567
5.
Clin Transl Gastroenterol ; 12(10): e00411, 2021 10 06.
Article in English | MEDLINE | ID: covidwho-1456553

ABSTRACT

INTRODUCTION: The adherence to a gluten-free diet (GFD) is a trending topic in the management of celiac disease. The aim of our study was to evaluate the diagnostic performance of urinary gluten immunogenic peptides (GIP) determination to detect gluten contamination of the GFD. METHODS: In study A, 25 healthy adults on a standard GFD performed 6 gluten challenges (0, 10, 50, 100, 500, and 1,000 mg) with quantification of urinary GIP before (T0) and during the following 24 hours. In study B, 12 participants on a gluten contamination elimination diet underwent urinary GIP determination at T0 and after challenge with 5 or 10 mg gluten. Urine GIP concentration was determined by an immunochromatographic assay. RESULTS: In study A, 51 of 150 baseline urine samples were GIP+ on GFD and 7 of 17 were GIP+ after the zero-gluten challenge, whereas only 55 of 81 were GIP+ after the 10-1,000 mg gluten challenges. There was no significant change in the 24-hour urinary GIP when increasing gluten from 10 to 1,000 mg. In study B, 24 of 24 baseline urine samples were GIP-, whereas 8 of 24 were GIP+ after 5 or 10 mg of gluten. DISCUSSION: Traces of gluten in the standard GFD may cause positivity of urinary GIP determination, whereas a false negativity is common after a gluten intake of 10-1,000 mg. Owing to the impossibility of standardizing the test in normal conditions, it seems unlikely that urinary GIP determination may represent a reliable tool to assess the compliance to the GFD of patients with celiac disease or other gluten-related disorders.


Subject(s)
Celiac Disease/diet therapy , Celiac Disease/urine , Diet, Gluten-Free , Glutens/urine , Patient Compliance , Peptides/urine , Adult , Celiac Disease/immunology , Double-Blind Method , Female , Glutens/immunology , Humans , Immunoglobulin A/blood , Male , Peptides/immunology , Transglutaminases/immunology
SELECTION OF CITATIONS
SEARCH DETAIL